
What We're Reading: Vape Flavor Ban Reversal; FDA Approves Sickle Cell Drug; FTC Clears BMS–Celgene Merger
After saying he would back a ban on flavored vapes, President Trump now says he wants to study the issue more; the FDA approved Novartis’ crizanlizumab (Adakveo) as both monotherapy and in combination for patients 16 years or older with sickle cell disease; the Federal Trade Commission will allow Bristol-Myers Squibb to purchase Celgene for $74 billion in cash and stocks.
Trump Backs Away From Ban on Vape Flavors
FDA Approves New Drug to Treat Sickle Cell Disease
With more than 40 deaths now on record caused by vaping and increasing reports of severe lung injuries, support rose for a ban on flavored e-cigarettes. After saying he would back such a ban, President Trump now says he wants to study the issue more, according to
Bristol-Myers Squibb/Celgene Merger Given the Go-Ahead
On the condition that they sell apremilast (Otezla)—which will become the largest divestiture on record—the Federal Trade Commission will allow Bristol-Myers Squibb to purchase Celgene for $74 billion in cash and stocks, in what
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.